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Abstract
Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation
antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of SGAs;
followed by a secondary decrease possibly due to the negative feedback from the SGA-induced body
weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. Moreover, the results can
also vary depending on individual SGAs, other hormonal states, dietary choices, and other confounding
factors including medical history, co-treatments, age, gender, and ghrelin measurement techniques.
Interestingly, rats treated with olanzapine, an SGA with high weight gain liabilities, are associated with
increased hypothalamic ghrelin receptor (GHS-R1a) levels. In addition, expressions of downstream ghrelin
signalling parameters at the hypothalamus, including neuropeptide Y (NPY)/agouti-related peptide (AgRP)
and proopiomelanocortin (POMC) are also altered under SGA treatments. Thus, understanding the role of
ghrelin signalling in antipsychotic drug-induced weight gain should offer potential novel pharmacological
targets for tackling the obesity side-effect of SGAs and its associated metabolic syndrome.
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ABSTRACT
Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation
antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of
SGAs; followed by a secondary decrease possibly due to the negative feedback from the SGAinduced body weight gain or hyperphagia; and a final re-increase to reach the new equilibrium.
Moreover, the results can also vary depending on individual SGAs, other hormonal states, dietary
choices, and other confounding factors including medical history, co-treatments, age, gender, and
ghrelin measurement techniques. Interestingly, rats treated with olanzapine, an SGA with high
weight gain liabilities, are associated with increased hypothalamic ghrelin receptor (GHS-R1a)
levels. In addition, expressions of downstream ghrelin signalling parameters at the hypothalamus,
including neuropeptide Y (NPY)/ agouti-related peptide (AgRP) and proopiomelanocortin (POMC)
are also altered under SGA treatments. Thus, understanding the role of ghrelin signalling in
antipsychotic drug-induced weight gain should offer potential novel pharmacological targets for
tackling the obesity side-effect of SGAs and its associated metabolic syndrome.
KEYWORDS:
Antipsychotic; ghrelin; AMPK; neuropeptides; obesity; hypothalamus
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1. Introduction
Schizophrenia is a complex mental disorder affecting approximately 1.5% of the adult population
worldwide (Bhugra, 2005). Second-generation antipsychotics (SGAs) have become the primary
treatment for schizophrenia and other psychotic disorders due to their claimed superior efficacy and
induction of fewer extrapyramidal side-effects compared to the first-generation antipsychotics
(Kane et al., 2009; Leucht et al., 2009a; Leucht et al., 2009b). However, metabolic side-effects, in
particular body weight gain, have emerged as an increasing concern for SGAs in light of their
accompanying complications and deterioration in drug compliance (Lieberman et al., 2005).
Although some valuable insights have been achieved, the mechanism of SGA-induced weight gain
remains unclear.
Ghrelin is a 28-amino-acid orexigenic hormone secreted mainly from the X/A-like cells (rodent
equivalent of the human P/D1 cells) at the fundus of the stomach (Kojima et al., 1999; Nakazato et
al., 2001; Tschop et al., 2000). Ghrelin could increase food intake and lead to body weight gain in
humans (Adachi et al., 2010; Druce et al., 2005), which coincides with clinical observations that
patients on antipsychotics often experience increased appetite and food intake. In addition, clinical
(Basoglu et al., 2010; Chen et al., 2011; Esen-Danaci et al., 2008; Hosojima et al., 2006; Kim et al.,
2008; Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al., 2008;
Roerig et al., 2008; Tanaka et al., 2008; Togo et al., 2004; Vidarsdottir et al., 2010) and animal
studies (Albaugh et al., 2006; Davey et al., 2012; Weston-Green et al., 2011) suggest that SGA
treatments modulate circulating ghrelin levels. Moreover, rats treated with olanzapine, an SGA with
significant weight gain liabilities, have elevated hypothalamic ghrelin receptor (also called growth
hormone secretagogue receptor 1a; GHS-R1a) expression (Davey et al., 2012; Zhang et al., 2012),
indicating that ghrelin signalling may play a role in antipsychotic-induced obesity.
Multiple factors, such as the antagonism of the histaminergic H1 receptor and serotoninergic 5HT2c receptors have been suggested as important factors contributing to the weight gain side-effect
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induced by SGAs (Kroeze et al., 2003; Nasrallah, 2008; Reynolds and Kirk, 2008); and the role of
α-adrenergic (Nasrallah, 2008), muscarinic M3 (Weston-Green et al., 2012b), and histaminergic H3
(Deng et al., 2010) antagonism has also been suggested. However, we have very limited
understanding of the role of ghrelin signalling in SGA-induced body weight gain. Considering the
fact that ghrelin is an important orexigenic circulating hormone, as well as the presence of GHSR1a and ghrelin at the hypothalamic arcuate nucleus (Arc), the energy homeostasis regulatory
centre, elucidating the molecular mechanisms of ghrelin signalling under SGA treatments may
assist in exploring pharmacological targets for tackling the weight gain side-effects of SGAs.
2. The ghrelin signalling system
2.1 Ghrelin and the ghrelin receptor
The biochemical features and orexigenic actions of ghrelin and the ghrelin receptor have been
reviewed previously (Andrews, 2011a; Castaneda et al., 2010; Schellekens et al., 2010). Ghrelin is
posttranslationally acylated by the enzyme ghrelin O-acyltransferase (GOAT) on Ser3 of the ghrelin
peptide, which is essential for binding ghrelin to the GHS-R1a receptor (Andrews, 2011b; Bednarek
et al., 2000; Schellekens et al., 2010; Yang et al., 2008). The GHS-R1a receptor is highly expressed
in the Arc, where food intake and energy homeostasis are regulated (Harrold et al., 2008).
Recent findings of the heterodimerization between the GHS-R1a receptor and other G proteincoupled receptors, including the dopaminergic D1 and D2, the serotoninergic 5-HT2c, and the
melanocortinergic MC4 receptors (Jiang et al., 2006; Kern et al., 2012; Rediger et al., 2011;
Schellekens et al., 2013), have shed light on novel mechanisms of food intake and body weight
regulation via the ghrelinergic system. Further, SGAs such as olanzapine and clozapine are
antagonists of the D2 and 5-HT2c receptors, which induces weight gain (Nasrallah, 2008). Hence
the weight gain liabilities of these SGAs can also be due to the functional interactions between these
receptors and the GHS-R1a receptor.
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2.2 Transduction of ghrelin signals from the peripheral to the brain
Several lines of evidence support the role of the vagus-nucleus of the solitary tract (NTS)-Arc
pathway in ghrelin signal transduction from the peripheral to the brain (Fig.1a). Blockade of the
gastric vagal afferent pathways by either vagotomy or capsaicin application abolished peripheral
ghrelin-induced feeding in rats (Chen et al., 2005; Date et al., 2002), mice (Asakawa et al., 2001),
and humans (le Roux et al., 2005), although contradictory results exist in rats (Arnold et al., 2006).
Further, the GHS-R1a receptor is also expressed in the nodose ganglion of the stomach-projected
vagal afferent neurons (Sakata et al., 2003), which synapse centrally at the NTS. The NTS is the
termination area of the vagal afferents which receive viscerosensory information from the
gastrointestinal tract, and contains the A2 noradrenergic neurons which project to numerous
hypothalamic nuclei including the Arc (Sawchenko and Swanson, 1981).
Direct action of ghrelin on the hypothalamic Arc through the blood-brain barrier (BBB) is also
possible (Fig.1a), since saturable transport of acylated ghrelin across the BBB has been evidenced
(Banks et al., 2002; Pan et al., 2006). An alternative pathway could be the binding of ghrelin to the
GHS-R1a receptor at the dorsal vagal complex (DVC) of the brainstem, in particular the area
postrema (AP) where the BBB is incomplete, and projects to the hypothalamus (Fig.1a). Selective
ablation of the AP blocks pancreatic secretion triggered by intravenous infusion of ghrelin, which
was substantiated by the elimination of the ghrelin-induced c-fos expression at the AP, NTS and
dorsal motor nucleus of the vagus (DMV) (Li et al., 2006). Finally, a small amount of ghrelin is
produced in the hypothalamus, since ghrelin-containing neurons have been detected in the Arc (Lu
et al., 2001) as well as in an area adjacent to the third ventricle and between the Arc, the
dorsomedial hypothalamus (DMH), the ventromedial hypothalamus (VMH) and the paraventricular
nucleus (PVN) (Cowley et al., 2003).
2.3 Central ghrelin signalling and food intake
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The involvement of ghrelin signalling adds a new dimension to the hypothalamic network of energy
balance regulation (Fig.1b). At the Arc, ghrelin can upregulate NPY and AgRP and downregulate
POMC expressions, contributing to the orexigenic effect of ghrelin. Interestingly, the SGA
olanzapine has been reported to upregulate NPY and AgRP, and downregulate POMC at the
hypothalamic Arc (Fernø et al., 2011; Weston-Green et al., 2012a), suggesting that ghrelin
signalling can be involved in the SGA-induced elevation of food intake.
The regulation of NPY and AgRP expressions in the Arc NPY/AgRP neurons by ghrelin via the
AMP-activated protein kinase (AMPK) signalling is reviewed by Andrews (Andrews, 2011a).
Briefly, activation of the GHS-R1a receptor at the level of Arc NPY/AgRP cells promotes
mitochondria β-oxidation, tentatively through the AMPK – carnitine palmitoyltransferase 1 (CPT1)
– uncoupling protein 2 (UCP2) pathways. Central inhibition of AMPK signalling reduced the
orexigenic effect of ghrelin (López et al., 2008), and blocked the ghrelin-induced fatty acid synthase
downregulation. Further, fasting-induced elevation of hypothalamic AMPK is associated with
decreased malonyl-CoA and increased CPT1 activity (López et al., 2008). Finally, the postprandial
suppression of AMPK was eliminated in UCP2 knockout but not in wild type mice (Andrews et al.,
2008). More recent studies have also indicated the roles of Sirtuin 1 (SIRT1)/p53 (Velasquez et al.,
2011) and CPT1c/ceramide (Ramirez et al., 2013) in the orexigenic effect of ghrelin signalling.
Moreover, the mammalian target of rapamycin (mTOR) signalling pathway has also been suggested
as an alternative pathway which mediates the orexigenic actions of ghrelin (Martins et al., 2012).
The role of intracellular transcriptional factors in ghrelin-induced alterations of hypothalamic
neuropeptides (Fig.2) has been highlighted recently (Lage et al., 2010). The forkhead box O1
(FOXO1) and the phosphorylated cAMP-response element-binding protein (pCREB) have been
demonstrated as transcriptional factors for the expression of AgRP and NPY, respectively (Kim et
al., 2006; Kitamura et al., 2006; Sakkou et al., 2007; Shimizu-Albergine et al., 2001). FOXO1 is
translocated into the nucleus of AgRP neurons, where it stimulates AgRP promoter activity (Kim et
6

al., 2006; Kitamura et al., 2006). Additionally, FOXO1 also stimulates NPY transcription by
binding to the NPY promoters (Kim et al., 2006), and inhibits POMC promoter activity (Kim et al.,
2006; Kitamura et al., 2006), possibly by opposing the effect of signal transducer–activated
transcript-3 (STAT3) (Kim et al., 2006). Recently FOXO1 knock-in mice with specific activation at
the hypothalamus and pancreas have been reported to develop obesity and hyperphagia, with
increased hypothalamic AgRP and NPY levels (Kim et al., 2012). It is suggested that the brainspecific homeobox transcription factor (BSX) regulates both AgRP and NPY expression directly,
and interacts with FOXO1 and pCREB, producing synergistic effects on the expression of AgRP
and NPY, respectively (Sakkou et al., 2007). Interestingly, central administration of ghrelin
increased the mRNA expression of BSX in the Arc and the protein expression of FOXO1 and
pCREB in the hypothalamus in rodents (Lage et al., 2010; Nogueiras et al., 2008).
3. Effects of SGAs on the ghrelin signalling system
Previous reports have suggested controversial results of the effect of SGAs on circulating ghrelin
levels (Sentissi et al., 2008; Jin et al., 2008). One earlier review paper suggested a bi-phasic effect,
with downregulated and upregulated ghrelin levels under short- and long-term SGA treatments,
respectively (Sentissi et al., 2008). Another review paper has proposed preliminary explanation
suggesting that the negative feedback effect of ghrelin secretion is disrupted under SGA treatments
in the long-term (Jin et al., 2008). Nevertheless, as more studies are added to the pool of knowledge
on ghrelin levels under SGA treatments, these views are challenged and a re-evaluation is required.
SGAs produced seemingly controversial effects on circulating ghrelin levels in both humans (Table
1) and animals (Table 2). However, a detailed analysis on these studies according to the length of
treatment reveals a tri-phasic effect of SGAs on ghrelin levels: an initial upregulatory effect; a
downregulatory negative feedback effect in the short- to mid-term; and a final increase effect in the
long-term (Fig. 3).
3.1 Initial effects of SGAs on circulating ghrelin production
7

No clinical studies have reported on the acute effect of SGAs on circulating ghrelin levels, which
makes the judgement of the initial effect of SGAs over ghrelin production difficult. However, one
short-term study suggested that eight days of olanzapine treatment can lead to small but significant
increase in pre- and postprandial total ghrelin levels (Vidarsdottir et al., 2010), indicating an acute
upregulatory effect of SGAs on ghrelin production. This view is supported by two pharmacological
animal studies which showed that acute olanzapine or clozapine treatments can increase both preand postprandial total ghrelin levels in rodents (van der Zwaal et al., 2012). Furthermore, our
preliminary data also showed that one week of oral olanzapine treatment can increase plasma total
ghrelin levels in rats (Zhang et al., unpublished data). Therefore, an initial upregulatory effect of
SGAs on circulating ghrelin production is proposed.
Neuronal control of ghrelin secretion includes vagal (parasympathetic) and sympathetic pathways
(Fig. 4). The preprandial elevation and postprandial suppression of circulating ghrelin levels are
both exaggerated by vagal stimulation (Heath et al., 2004). An inhibitory tone of vagus nerve over
ghrelin production has been suggested (Lee et al., 2002; Toshinai et al., 2001; Weston-Green et al.,
2012b), which was supported by a truncal vagotomy study showing that plasma ghrelin was
increased by vagotomy in rats (Lee et al., 2002), and ghrelin secretion is increased during fasting
when vagal (parasympathetic) activity is low. Since olanzapine and clozapine, the two SGAs with
highest risk of weight gain, are both muscarinic M1 and M3 antagonists (Nasrallah, 2008), it is
conceivable that the blockage of vagal (parasympathetic) signalling pathways by these SGAs
promotes ghrelin production (Weston-Green et al., 2012b). However, this view is in contrary to the
findings of another subdiaphragmatic vagotomy study which showed that fasting-induced elevation
of ghrelin levels was completely prevented by subdiaphragmatic vagotomy, and significantly
reduced by a muscarinic antagonist atropine (Williams et al., 2003). Two pharmacological studies
also suggested that ghrelin secretion was stimulated by cholinergic/muscarinic agonists, while
inhibited by muscarinic antagonists (Broglio et al., 2004; Hosoda and Kangawa, 2008). Further, it is
noteworthy that although clozapine is a muscarinic receptor antagonist, norclozapine (an active
8

metabolite of clozapine) is a partial agonist of muscarinic receptors (Davies et al., 2005; Li et al.,
2005). Therefore, the individual variations on the clozapine: norclozapine ratio (Couchman et al.,
2010) explain, at least partly, the variations of findings in studies reporting on ghrelin levels under
SGA treatments.
Studies on sympathetic (in particular adrenergic) control of ghrelin production also provide indirect
support for the view that SGAs can upregulate ghrelin production. One pharmacological study
showed that ghrelin secretion in rats was stimulated by an α-adrenergic antagonist phentolamine
and a β-adrenergic agonist isoproterenol, while inhibited by an α-adrenergic agonist phenylephrine
(Hosoda and Kangawa, 2008), suggesting an inhibitory role of α-adrenergic signalling and a
facilitatory role of β-adrenergic signalling on ghrelin secretion. Similarly, an earlier study also
found that intraperitoneal injections of the selective α1-adrenergic receptor antagonist prazosin
(0.25mg/kg), the α2-adrenergic receptor antagonist yohimbine (2mg/kg), and the SGA clozapine
(10mg/kg) significantly increased blood active ghrelin levels in male Sprague-Dawley rats
(Murashita et al., 2007b). Since most SGAs are antagonists of α1- and α2-adrenergic receptors
(Nasrallah, 2008), increased ghrelin levels under SGA treatments could be expected. Taken
together, the balance between cholinergic and adrenergic signals combined with the antagonist
and/or partial agonist properties of SGAs on the corresponding receptors provides a possible
explanation for the initial effects of SGAs on ghrelin production.
3.2 Secondary effects of SGAs on circulating ghrelin levels
After the appearance of the initial upregulatory effect on ghrelin production, during the short- to
mid-term of the SGA treatments, results from clinical studies become more inconsistent. One study
investigated the effect of olanzapine, clozapine, antidepressants with weight gain, other
antipsychotics, and other antidepressants on circulating ghrelin levels showed that after 8-14 days of
treatment, there was no significant difference in circulating total ghrelin levels amongst treatment
groups (Himmerich et al., 2005). Other short- to mid-term studies suggested that circulating total
9

ghrelin levels are decreased compared to the baseline or control after 2-6 weeks of SGA treatments
(Basoglu et al., 2010; Roerig et al., 2008; Tanaka et al., 2008; Vidarsdottir et al., 2010). These
findings indicate that after the initial upregulatory effect, ironically, SGAs produced a
downregulatory effect on the circulating ghrelin levels during the short- to mid-term of the
treatments in humans, which can cancel out the initial upregulatory effect or even push the levels
further below the baseline. Interestingly, animal studies also showed a similar trend, with one study
showing no difference in active ghrelin levels (Albaugh et al., 2006) and another study showing
decreased total ghrelin levels (Davey et al., 2012) after 2-3 weeks of olanzapine treatments;
although another 2-week study still shows an upregulatory effect in total ghrelin levels (WestonGreen et al., 2011). Moreover, our unpublished data also showed that after 2 weeks and 5 weeks of
treatment, there was no difference in plasma total ghrelin levels between the olanzapine and control
groups (Zhang et al., unpublished data). Together, these data may suggest a secondary
downregulatory effect of SGAs on circulating ghrelin levels, which could be due to the increased
body weight and food intake triggered by the initial SGA treatment. In fact, ghrelin levels are lower
in obese humans (Tschop et al., 2001), and the SGA-treated patients in the above-mentioned shortto mid-term clinical studies had significantly increased body weight (Hosojima et al., 2006; Roerig
et al., 2008) or BMI (Basoglu et al., 2010), indicating a possible negative feedback mechanism of
reduced ghrelin levels in response to SGA-induced weight gain.
3.3 Longer term effects of SGAs on circulating ghrelin levels
Clinical studies reporting on ghrelin levels after 8-16 weeks of SGA treatments showed that neither
total (Popovic et al., 2007; Smith et al., 2012; Tanaka et al., 2008) nor active (Tanaka et al., 2008;
Theisen et al., 2005) ghrelin levels during these treatment periods were significantly different from
the baseline or control (Table 1), indicating a recovery of ghrelin levels to the baseline after the
secondary downregulatory effects of SGA-induced weight gain. These findings are in accordance
with an 8-week animal study which showed that 8 week of olanzapine, haloperidol or vehicle
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control treatments had no significant difference in circulating ghrelin levels in mice. Furthermore,
the majority of longer-term studies reporting on ghrelin levels after more than 6 months of SGA
treatments showed an upregulation effect of SGAs on circulating total (Esen-Danaci et al., 2008;
Murashita et al., 2007a; Murashita et al., 2005), active (Murashita et al., 2007a; Murashita et al.,
2005; Palik et al., 2005) or desacyl (Perez-Iglesias et al., 2008) ghrelin levels, with the exception of
two studies (Chen et al., 2011; Kim et al., 2008) (see details in Table 1). Interestingly, both of these
two studies reported on total ghrelin levels only (Chen et al., 2011; Kim et al., 2008); while the
three long-term studies reported on active ghrelin levels all indicated that SGAs can increase ghrelin
levels (Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005). Since acyl ghrelin (noctanoyl ghrelin) is the biologically active form of ghrelin which binds to the GHS-R1a receptor to
exert its orexigenic effect (as mentioned earlier in section 2.1), it might be more relevant in the
context of SGA-induced body weight gain compared to total ghrelin, although SGAs, as suggested
by another study, also increase desacyl (inactive) ghrelin levels in the long-term (Perez-Iglesias et
al., 2008). Together, these studies suggested that circulating ghrelin levels return to the levels of, or
even above baseline after long-term SGA treatments. The exact mechanism for this phenomenon is
still unknown, although the re-establishment of a new energy balance after the weight gain induced
by SGAs could be a possible explanation.
In summary, existing clinical and animal studies suggest that SGAs have an initial upregulatory
effect on circulating ghrelin levels during the acute- to short-term treatment stage (Fig. 3). This
effect is possibly due to the direct effect of SGAs on ghrelin production through neuronal
regulations over the parasympathetic and sympathetic pathways. After the initial upregulation,
SGA-induced weight gain produced a downregulatory effect on circulating ghrelin levels during
short- to mid-term treatments (Fig. 3). At this stage of treatments, human or animal subjects treated
with SGAs have increased body weight and food intake triggered by the initial SGA treatments,
which could produce a negative feedback control on circulating ghrelin levels, resulting in the
overall seemingly downregulatory effect. Eventually, a new energy balance is re-established and the
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negative feedback effects of the increased body weight and food intake on ghrelin levels are
removed, leading to the recovery of circulating ghrelin levels back to the baseline level or above
during the longer term of SGA treatments.
3.4 Other possible explanations for the effect of SGAs on circulating ghrelin levels
The discrepancies of the results in clinical studies may also be due to differing medication histories
and possible co-treatments within study subjects (in particular those who had been treated with
other antipsychotics), different age range and/or gender composition, and different ghrelin
measurement techniques used in different studies (see Table 1 for details). Further, different
antipsychotics can have diverse effects on ghrelin secretion. For example, clozapine tend to have no
effect on ghrelin levels in the short-term (Himmerich et al., 2005; Popovic et al., 2007; Theisen et
al., 2005), and risperidone tend to increase ghrelin levels in the long-term (Esen-Danaci et al., 2008;
Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al., 2008). Moreover, differing patient
hormonal states (other than ghrelin) may also affect ghrelin production. For instance, ghrelin
secretion was reduced by insulin (Kamegai et al., 2004; Shrestha et al., 2009), and increased by
cholecystokinin (CCK) (Shrestha et al., 2009) and glucagon (Kamegai et al., 2004). Finally,
differing dietary choices by study subjects could be another confounding factor for ghrelin
production, since a high-carbohydrate diet produced a more persistent postprandial inhibitory effect
on ghrelin secretion than the high-fat diet (Monteleone et al., 2003; Sánchez et al., 2004), which
was presumably due to the different satiating capacities of these diets.
In the clinic, female has been suggested as a risk factor and predictor for weight gain associated
with SGAs and other antipsychotics (Gebhardt et al., 2009; Smith, 2010). In fact, the sensitivity of
female rodents to the weight gain side-effect of SGAs over males is comparable to that in the clinic
(Weston-Green et al., 2010). However, only one human study has reported on gender differences in
ghrelin levels under SGA treatments, but this study showed no gender effect (Himmerich et al.,
2005). In contrast, one recent rodent study reported that plasma ghrelin levels were reduced by
12

olanzapine in females but not in males (Davey et al., 2012). Further studies are required to compare
the gender differences in the effects of SGAs on ghrelin levels.
3.5 SGAs upregulate GHS-R1a receptor expressions in the hypothalamus
In addition to the effects on circulating ghrelin levels, SGAs (in particular olanzapine) have also
been reported to upregulate hypothalamic levels of the GHS-R1a protein and mRNA expression
(Davey et al., 2012; Zhang et al., 2012). This could be the results of the initial upregulated ghrelin
(especially active ghrelin) levels under SGA treatments. Growth hormone-releasing hormone
(GHRH) and growth hormone secretagogue (GHS) have been reported to upregulate GHS-R1a
mRNA expression in rat pituitaries (Kineman et al., 1999), and ghrelin has been reported to activate
GHS-R1a in the rat retina (Zaniolo et al., 2011). In addition, ghrelin treatment reversed the downregulated GHS-R1a mRNA and protein levels in the rat cerebral cortex on ischemia/reperfusion
injury (Miao et al., 2007), and intravenous injection of ghrelin upregulated GHS-R1a mRNA at the
Arc of the hypothalamus in rats (Nogueiras et al., 2004). Therefore, it is conceivable that elevated
blood ghrelin levels under SGA treatments upregulate hypothalamic GHS-R1a expression.
As a possible example, it has been recently reported that some of the dopamine D2 receptor is
colocalized with the GHS-R1a receptor at the hypothalamus, and heterodimers of D2 receptor and
the GHS-R1a receptor have been found to naturally exist in cells coexpressing these receptors with
functional interactions (Kern et al., 2012). Since most SGAs are D2 receptor antagonists, it is
possible that blocking the D2 receptor by these antipsychotics stimulates the expression of the
GHS-R1a receptor by a compensatory mechanism. In addition, the D2 receptor agonist requires the
GHS-R1a receptor to conduct the anorexic effect (Kern et al., 2012). Conversely, is it conceivable
that SGAs, as D2 antagonists, require the integrity of the GHS-R1a receptor to increase food intake.
In fact, reduced D2 receptor concentration was detected in obese rats as opposed to lean rats
(Fetissov et al., 2002; Palmiter, 2007). Furthermore, heterodimerization and functional interaction
between the GHS-R1a receptor and the 5-HT2c receptor has also been identified recently
13

(Schellekens et al., 2013). Since most SGAs, in particular those with high weight gain liabilities are
5-HT2c antagonists, it is possible that these SGAs may regulate ghrelin signalling via antagonising
the 5-HT2c receptors, or vice versa. Finally, the heterodimers between the GHS-R1a receptor and
the melanocortin-3 receptor (MC3R) (Rediger et al., 2011), and between the GHS-R1a receptor and
the dopamine D1 receptor (Jiang et al., 2006) have been reported.
3.6 Ghrelin signalling and the rewarding system in SGA-induced weight gain
Apart from the effects on the hypothalamic energy homeostatic regulation system, ghrelin
signalling can also contribute to SGA-induced weight gain through the food rewarding system.
Ghrelin signalling has been suggested to play a key role in food reward behaviour (for review see
(Schellekens et al., 2012)). Briefly, the GHS-R1a receptor is also expressed in extra-hypothalamic
areas such as the ventral tegmental area (VTA) and lacterodorsal tegmental area (LDTg) (Guan et
al., 1997), which are important nodes in the mesolimbic dopaminergic rewarding circuit. Further,
ghrelin has also been shown to activate the mesolimbic rewarding system as VTA ghrelin injection
increases food intake in rodents (Naleid et al., 2005), and dopamine release at the nucleus
accumbens (NAc) can be stimulated by ghrelin (Jerlhag et al., 2006; Jerlhag et al., 2007).
Interestingly, SGAs, including olanzapine, have been suggested to deteriorate the pre-existing
hedonic alterations (enhanced anticipation of food reward) in schizophrenia patients (Elman et al.,
2006; Mathews et al., 2012). However, to the best of our knowledge, the role of rewarding system
through ghrelin signalling in SGA-induced weight gain has not yet been reported. Given the fact
that the GHS-R1a receptor has been reported to form heterodimers with D1, D2, and 5-HT2c
receptors (Jiang et al., 2006; Kern et al., 2012; Schellekens et al., 2013), the interactions between
the ghrelinergic system and the mesolimbic dopaminergic/mesocortical serotoninergic rewarding
system in SGA-induced weight gain and hyperphagia warrant further study.
4. Conclusions and clinical implications
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SGAs have been associated with more serious hyperphagia, adiposity and body weight gain
compared to the first-generation antipsychotics. Clinical data has indicated ghrelin production and
signalling is upregulated, at least in a subpopulation of patients under SGA treatments (Esen-Danaci
et al., 2008; Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al.,
2008), which was supported by the majority of acute and chronic animal studies (Murashita et al.,
2007b; van der Zwaal et al., 2012; Weston-Green et al., 2011). Although ghrelin signalling is only
indirectly related to SGAs, and therefore other mechanisms (for example, antagonism of H1, H3, 5HT2a, M3 receptors) cannot be excluded, the majority of data as discussed above indicate that the
altered ghrelin signalling under SGA treatments can at least partly explain the weight gain sideeffects induced by SGAs. In addition, it has been suggested that ghrelin induces adiposity (Choi et
al., 2003) and suppresses energy expenditure (Asakawa et al., 2001; Tang-Christensen et al., 2004),
independent of its effect on body weight gain, which also coincide with the effects of SGAs with
weight gain liabilities (Albaugh et al., 2011; Evers et al., 2010; Monda et al., 2008; Skrede et al.,
2012; Stefanidis et al., 2009; van der Zwaal et al., 2010).
Based on existing data, it is conceivable that SGAs upregulate ghrelin production through a
complex regulation system involving the balance between sympathetic and parasympathetic
nervous systems. The elevated ghrelin signals are conducted to the hypothalamus, the energy
homeostasis regulation centre, through neuronal afferent pathways, or to a lesser extent, through
direct actions at the Arc or DVC by passing through the BBB. The GHS-R1a receptor expression at
the hypothalamus is also upregulated under SGA treatments (Davey et al., 2012; Zhang et al., 2012),
possibly through the elevated circulating ghrelin levels. The elevated ghrelin signals integrated at
the hypothalamus upregulate the Arc orexigenic neuropeptides AgRP and NPY, possibly through
the activation of the transcription factors BSX, FOXO1 and pCREB. Innervated NPY/AgRP
neurons at the Arc can thus inhibit the nearby POMC neurons, further enhancing the hyperphagic
signals of ghrelin, leading to body weight gain.
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It has been suggested that SGAs’ weight gain liabilities are associated with their antagonism on H1,
5-HT2a, 5-HT2c and D2 receptors. While SGAs act on each of these systems independently and
contribute to the weight gain side-effects, these systems also interact with the ghrelinergic system to
create a synergistic effect on food intake and body weight gain. Given the fact that the GHS-R1a
receptor can form heterodimers and have functional interactions with the 5-HT2c and D2 receptors,
further research is required to untangle the relationships of the effects of SGAs on these systems
and to elucidate the exact mechanisms of SGA-induced hyperphagia and weight gain.
Considering the increased ghrelin levels in patients after weight loss, inhibiting ghrelin signalling
by blocking/antagonising the GHS-R1a receptor may be an attractive strategy to maintain body
weight loss and to prevent body weight gain under SGA treatments. Furthermore, animal studies
have revealed that weight reduction by food restriction not only increases circulating ghrelin levels,
but also the level of the GHS-R1a receptor at the hypothalamus and the sensitivity of GHS-R1a to
ghrelin receptor agonists. Thus, blocking ghrelin signalling by GHS-R1a antagonists or inverse
agonists could be a promising strategy to help maintain weight loss in SGA-induced obese patients.
In fact, [D-Lys-3]GHRP-6, a GHS-R1a antagonist, has been reported to reduce food intake and
body weight gain in mice (Asakawa et al., 2003) and rats (Beck et al., 2004). Therefore, whether
GHS-R1a antagonists are effective targets in attenuating hyperphagia and body weight gain in an
animal model and translating these results into clinical studies warrants further research. Finally, to
elucidate the role of ghrelin signalling in SGA-induced weight gain, future studies should also
investigate the effects of SGAs on energy balance regulation in ghrelin signal-deficient models (e.g.
ghrelin-knockout or GHSR-knockout animals). In conclusion, recognizing the upregulation of
ghrelin signalling under SGA treatments could lead to novel therapeutic approaches for tackling the
weight gain side-effects of SGAs.
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Table 1. Effect of SGAs on circulating ghrelin levels – Human Studies
Reference

Study characteristics

Short‐term (less than 4 months):
Smith et al., 2012
n=13‐17/group; mean age 41 years
97.8% male; schizophrenic patients
Olz or Ris (average 25.2mg/d or 6.1mg/d)
Duration: 2 months

Ghrelin measures

Findings

Total ghrelin (RIA)

No difference in ghrelin response to fatty meal between Olz and Ris
treated patients. No difference in ghrelin levels between Olz and Ris
treated patients, or between endpoint and baseline. Olz induced a slight
but significant increase in body weight compared to baseline (+ 4.19 kg,
P=0.009)

Vidarsdottir et al.,
2010

n=10; age 20‐40 years
100% male; healthy; crossover design
Olz (10mg/d)
Duration: 8 days; diet controlled on day 7‐8

Total ghrelin (RIA)

Pre‐ and post‐prandial ghrelin increased slightly compared to control at
dinner, but not at breakfast. Pre‐prandial CCK increased slightly at
breakfast only.

Basoglu et al., 2010

n=20‐22/group; mean age 21 years
100% male; drug naive psychosis patients
vs. healthy controls
Olz (10‐20mg/d)
Duration: 6 weeks

Total ghrelin
(ELISA)

Ghrelin levels decreased with Olz treatment. BMI, waist circumference,
triglyceride, and leptin levels increased. Pre‐treatment ghrelin levels in
patients were higher than healthy controls.

Tanaka et al., 2008

n=28; mean age 59.5 years
64.3% male; schizophrenic patients
Olz (10‐20mg/d)
Duration: 16 weeks

Total ghrelin (RIA)
Active ghrelin (RIA)

Total ghrelin decreased at 8, 12 and 16 weeks compared to baseline;
active ghrelin unchanged. Female patients had higher total ghrelin and
active ghrelin levels than male at both baseline and endpoint. No
significant correlation between changes in leptin and ghrelin levels.

Roerig et al., 2008

n=9‐10/group; mean age 32 years
21.4% male; healthy
Olz (10mg/d) or Ris (4mg/d)
Duration: 2 weeks

Total ghrelin (RIA)

Ghrelin AUC was lower in Olz than Ris, but no difference between Olz and
placebo or Ris and placebo. Ghrelin AUC decreased from baseline to
endpoint in Olz group, but not in the other groups. Olz group had higher
weight gain compared to placebo group.

Popovic et al., 2007

n=18 (‐20 controls); mean age 29 years
50% male; schizophrenic patients vs
healthy controls
Clz (300mg/d) or Ris (4mg/d)

Total ghrelin (RIA)

No change in ghrelin levels under SGA treatment. SGAs did not change
post OGTT insulin levels. SGA treated patients had increased BMI and
plasma leptin levels compared to baseline.

Reference

Study characteristics

Ghrelin measures

Findings

Duration: 3 months
Hosojima et al.,
2006

n=13; mean age 37 years
85.7% male; schizophrenic patients
Olz (average 14.5mg/d)
Duration: 4 weeks

Active ghrelin (RIA)

Serum ghrelin levels decreased after Olz treatment. Body weight and
serum leptin levels increased. No change in insulin or fasting glucose
levels.

Himmerich et al.,
2005

n=6‐17/group; mean age 43.3 years
44.2% male; psychiatric patients
Olz or Clz (average 16.7mg/d or 150mg/d,
respectively), antidepressants with weight
gain, other antipsychotics, or other
antidepressants
Duration: 8‐14 days

Total ghrelin (RIA)

Ghrelin levels did not differ among treatment groups, and were not
related to gender. BMI at the time of ghrelin measure was negatively
correlated with ghrelin levels. Body weight increased in patients treated
with Olz or Clz.

Theisen et al., 2005

n=12; mean age 31 years
50% male; psychiatric patients
Clz (average 273mg/d)
Duration: 10 weeks

Active ghrelin (RIA)

Serum ghrelin levels at endpoint did not differ from baseline. BMI
increased by 1.3 kg/m2 compared to baseline (P<0.05). Serum leptin
levels increased.

Togo et al., 2004

n=15‐18/group; mean age 40.1 years
100% male; schizophrenic patients vs.
healthy controls (cross‐sectional)
Olz (10‐20 mg/d) or Ris (2‐6 mg/d)
Duration: 4 weeks or more

Active ghrelin (RIA)

Serum ghrelin levels lower in Olz or Ris treated patients than in healthy
controls. No significant difference found in ghrelin levels between Olz
and Ris treated patients. No significant difference in BMI between the
three groups.

Total ghrelin (RIA)

Olz treated patients with weight gain had lower ghrelin levels than
controls. Olz treated patients without weight gain had no difference in
ghrelin levels compared to controls.

Long‐term (more than 4 months):
Chen et al., 2011
n=21‐45/group (119 controls); mean age
38 years
50% male; schizophrenic patients vs.
healthy controls
Olz (DNS)
Mean duration: 8.3 years

Reference

Study characteristics

Ghrelin measures

Findings

Esen‐Danaci et al.,
2008

n=20‐28/group; mean age 34.3 years
48.1% male; psychiatric patients
Olz, Clz, Ris, Ami, or Que (DNS)
Duration: at least 1 year

Total ghrelin
(ELISA)

Olz/Clz/Ris/Ami, but not Que treated patients had higher ghrelin levels
than controls. No significant difference in serum leptin levels.

Kim et al., 2008

n=24; mean age 34.3 years
100% male; schizophrenic patients
Olz (5‐20mg/d)
Duration: 6 months

Total ghrelin (RIA)

Plasma ghrelin levels decreased during Olz treatment. Plasma leptin
levels increased. BMI and body weight increased (+1.9 kg/m2 and +6.5 kg
respectively, both P<0.01). Changes in ghrelin negatively correlated with
BMI, body weight, and leptin. No change in blood glucose levels.

Perez‐Iglesias et al.,
2008

n=21‐26/group; mean age 28.6 years
62.9% male; psychiatric patients
Olz (5‐20mg/d), Ris (3‐6mg/d), or Hal (3‐
9mg/d)
Duration: 1 year

Desacyl ghrelin
(ELISA)

Plasma ghrelin levels increased compared to baseline, but no difference
between treatment groups. Plasma insulin and leptin levels increased
compared to baseline, no difference between groups. Body weight and
BMI increased compared to baseline (+10.16 kg and +3.56 kg/m2,
respectively, both P<0.001), but no difference between groups.

Murashita et al.,
2007a

n=15 (25 controls); mean age 40.8 years
33.3% male; schizophrenic patients vs.
healthy controls
Ris (1‐5mg/d)
Mean Duration: 2.5 years

Total ghrelin (RIA)
Active ghrelin (RIA)

Total ghrelin and active ghrelin were higher in Ris group than in control
group. Ris treated group also had higher BMI and percentage body fat,
but not body weight, than control group.

Murashita et al.,
2005

n=7; mean age 46.3 years
57.1% male; schizophrenic patients
Olz (10‐15mg/d)
Duration: 6 months

Total ghrelin (RIA)
Active ghrelin (RIA)

Olz increased both total and active ghrelin levels compared to baseline.
Olz treated patients also increased body fat percentage and serum leptin
levels.

Palik et al., 2005

n=12‐15/group (75 controls); mean age
Active ghrelin (RIA) SGA treated patients had higher serum ghrelin levels than controls. No
50.6 years
difference in ghrelin levels or weight gain between the four
28.6% male; psychiatric patients vs.
antipsychotics. BMI of patient group is significantly higher than controls
healthy controls
(+5.0 kg/m2, P<0.0001). Significant negative correlation between ghrelin
Olz, Clz, Ris, or Que (DNS)
and BMI in SGA‐treated patients.
Duration: at least 1 year
Ami, amisulpride; AUC, area under curve; BMI, body mass index; CCK, cholecystokinin; Clz, clozapine; DNS, dosage not specified; ELISA, enzyme‐linked
immunosorbent assay; OGTT, oral glucose tolerance test; Olz, olanzapine; Que, quetiapine; RIA, radioimmuoassay; Ris, risperidone; SGA, second‐generation
antipsychotics.

Table 2. Effect of SGAs on circulating ghrelin levels and central GHSR1a expression – Animal Studies
Reference

Acute Studies:
Van der Zwaal et
al., 2012

Murashita et al.,
2007b

Chronic Studies:
Davey et al., 2012

Zhang et al., 2012

Study characteristics

Ghrelin measures

Findings

n=7‐8/group; male Wistar rats
Olz (1mg/kg; ip) or vehicle; acute
effect

Total ghrelin (RIA);
Active ghrelin
(Luminex)

Olz increased both total and active ghrelin levels preprandially and 45‐minute
postprandially compared to vehicle, but baseline levels of ghrelin were not affected
Olz counteracted the reduced meal size effect induced by CCK injection
Acute Olz treatment temporarily reduced locomotor activity and core body
temperature

n=5‐8/group; male S‐D rats
Clz (10mg/kg, acute
0/15/30/60min or 5/10/20mg/kg,
acute 30min; ip) or vehicle

Active ghrelin (RIA)

Clz (10mg/kg) increased ghrelin levels at 30 and 60min post‐injection
Clz (10mg/kg and 20mg/kg) increased ghrelin levels at 30 min post‐injection
Clz (10mg/kg) increased glucose levels at all times post injection
Prazosin (0.25mg/kg) and yohimbine (2mg/kg) also increased ghrelin levels 30min
post injection

n=8/group; male or female S‐D
rats
Olz (2mg/kg/d or 4mg/kg/d; ip;
bid) or vehicle
Duration: 3 weeks

Total ghrelin
(multi‐array assay);
Hypothalamic
GHSR1a mRNA
(Real‐time qPCR)

Female, but not male, rats treated with Olz (2mg/kg/d) had reduced circulating
ghrelin levels (p<0.05); 4mg/kg/d Olz tend to reduce ghrelin levels (p=0.068)
Olz induced weight gain in female rats only
Negative correlations between body weight gain and plasma ghrelin in female rats
only
Olz (4 mg/kg/d) increased hypothalamic GHSR1a mRNA expression in male rats only

n=6/group; female S‐D rats
Olz (3mg/kg/d; oral SA; tid) or
vehicle
Duration: 1, 2, or 5 weeks

Hypothalamic
GHSR1a protein
(Western‐blot)

Olz increased hypothalamic GHSR1a protein expression at 1, 2, and 5 weeks
Hypothalamus GHSR1a positively correlated with cumulative weight gain, and with
cumulative food intake at 1 and 2 weeks
Olz decreased hypothalamic POMC protein expression at 1, 2, and 5 weeks
Acute Olz treatment reduced BAT temperature in the 5‐week treatment group only

Reference

Study characteristics

Ghrelin measures

Findings

Weston‐Green et
al., 2011

n=12/group; female S‐D rats
Olz (0.75, 1.5, 3 or 6 mg/kg/d;
oral SA; tid)
Duration: 2 weeks

Total ghrelin (RIA;
4‐6h fasting)

Olz (all dosages) increased plasma ghrelin levels compared to control
Ghrelin positively correlated to body weight gain
Olz reduced plasma insulin (all dosages) and increase plasma CCK levels (in 1.5mg/d
and 6mg/d only)

Yamauchi et al.,
2010

n=7/group; female C57BL/6J mice
Olz, Hal (NS dosage and route) or
vehicle
Duration: 8 weeks

Active ghrelin
(ELISA)
Desacyl ghrelin
(ELISA)

No difference in active and desacyl ghrelin levels between Olz, Hal, and vehicle
Olz increased total body weight gain, size and number of adipocytes at 6 weeks

n=10‐12/group; male and female Active ghrelin (RIA) Olz had no significant effect on plasma ghrelin levels chronically in rats compared to
control
Wistar rats
Olz (4‐8mg/kg/d; oral SA; once/d)
Duration: 2 weeks
bid, twice per day; CCK, cholecystokinin; Clz, clozapine; ELISA, enzyme‐linked immunosorbent assay; GHSR1a, growth‐hormone secretagogue receptor 1a
(ghrelin receptor); Hal, haloperidol; ip, intraperitoneal; Olz, olanzapine; POMC, proopiomelanocortin; qPCR, quantitative PCR; RIA, radioimmuoassay; SA,
self‐administration; S‐D, Sprague‐Dawley; SGA, second‐generation antipsychotics; tid, three times per day.
Albaugh et al.,
2006
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Figure 1: Schematic illustration of afferent pathways of ghrelin signalling and the hypothalamic orexigenic system.
a. The upregulated ghrelin hormone under SGA treatment binds to the ghrelin receptors located at the GI tract and the vagal
afferents, from where the ghrelin signals are transmitted to the DVC of the brainstem. Alternatively, ghrelin can pass through
the BBB at the DVC and relay to the hypothalamus, or pass the BBB at the hypothalamus.
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arcuate nucleus, which exert an orexigenic effect by activating the orexigenic neurons at the LHA/PeF and inhibiting the
anorectic neurons at the PVN. NPY/AgRP neurons inhibit the nearby anorectic POMC neurons at the arcuate nucleus,
contributing to the overall elevation effect of ghrelin on food intake. Alternatively, ghrelin at the hypothalamus can also
directly influence neurons at the PVN and LHA/PeF, exerting the orexigenic effect.
Abbreviations: AgRP: agouti‐related peptide; Arc: arcuate nucleus; DMH: dorsal medial hypothalamus; DVC: dorsal vagal
complex; GI: gastrointestinal; LHA: lateral hypothalamic area; NPY: neuropeptide Y; POMC: pro‐opiomelanocortin; PVN:
paraventricular nucleus; VLM: ventrolateral medulla; VMH: ventral medial hypothalamus.
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Figure 2: Intracellular signalling pathways of ghrelin signalling in NPY/AgRP neuronal cells of the hypothalamic arcuate nucleus.
The upregulated ghrelin under SGA treatment will activate the ghrelin receptor (GHSR1a) at the NPY/AgRP neuronal cell membrane
located in the arcuate nucleus of the hypothalamus,
hypothalamus and through the AMPK
AMPK‐CPT1‐UCP2
CPT1 UCP2 pathway within these neuronal cells,
cells leading to
the upregulation of the transcriptional factors FOXO1, BSX and pCREB, and resulting in the increased expression of the orexigenic
neuropeptides NPY and AgRP.
Abbreviations: ACC: acetyl‐CoA carboxylase; AgRP: agouti‐related peptide; AMPK: 5’AMP‐activated protein kinase; BSX: brain‐specific
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ROS: reactive oxygen species; SIRT1: sirtuin 1; UCP2: uncoupling protein 2.
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Figure 3: The tri‐phasic effects of SGAs on circulating ghrelin levels over time
SGA treatments produced an acute upregulatory effect on the circulating ghrelin levels (t=0‐1 week), which triggers the increase of food
intake and body weight gain. The body weight gain can in turn lead to a secondary effect which reduces the level of ghrelin to baseline or
lower ((t=2‐6 weeks in humans and t=2‐3 weeks in rodents).
) After that,, a new energy
gy balance equilibrium
q
is re‐established,, and the
ghrelin levels return to the baseline or higher due to the continuous stimulus from the SGA treatments (t>6 weeks in humans and t>3
weeks in rodents). The blue solid square points represent data from clinical studies, and the red empty round points represent data from
rodent studies. The magnitude of changes shown in this figure is indicative for positive or negative values as compared to the baseline or
control values only. (t=0 represents data from acute studies).
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Figure 4: A potential mechanism of the role of ghrelinergic signalling in SGA‐induced weight gain
SGAs block the inhibitory vagal signals on ghrelin production by antagonising the M1/M3Rs (1); and alleviate the suppressive α‐
adrenergic signals by blocking the α1‐/ α2‐ ARs (2). Removing inhibitory signals increased ghrelin secretion from the stomach (3),
which stimulated the expression of GHS
GHS‐R1a
R1a at the NPY/AgRP neurons in the Arc of the hypothalamus (4).
(4) Enhanced ghrelinergic
signals stimulate NPY and AgRP expression in the Arc; hence orexigenic NPY/AgRP neurons are activated (5), which inhibits the
nearby anorexigenic POMC neurons, reducing the expression of POMC (6). The overall effect promotes food intake and adiposity
while suppressing energy expenditure (7), resulting in body weight gain (8).
Abbreviations: α1‐/α2‐ARs: α1‐/α2‐adrenergic receptors; ACh: acetylcholine; AgRP: agouti‐related peptide; Arc: arcuate nucleus; EE:
energy expenditure; FI: food intake; GHS‐R1a: ghrelin receptor; M1/M3R: M1‐/M3‐muscarinic receptors; NE: norepinephrine; NPY:
neuropeptide Y; POMC: pro‐opiomelanocortin.
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